All data are based on the daily closing price as of October 31, 2025
g
Green Cross Holdings
005250.KO
11.05 USD
-0.03
-0.27%
Overview
Last close
11.05 usd
Market cap
496.41M usd
52 week high
12.96 usd
52 week low
8.17 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
0.3169
Price/Book Value
0.7173
Enterprise Value
1.55B usd
EV/Revenue
0.9732
EV/EBITDA
5.8896
Key financials
Revenue TTM
1.59B usd
Gross Profit TTM
463.23M usd
EBITDA TTM
93.19M usd
Earnings per Share
N/A usd
Dividend
0.35 usd
Total assets
3.07B usd
Net debt
1.05B usd
About
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille's syndrome. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies, and clinical trials. Green Cross Holdings was founded in 1967 and is headquartered in Yongin-Si, South Korea.